Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis.

Wagner, Jamie L; Jones, Bruce M; Stover, Kayla R; Cleary, John D; Bland, Christopher M; Schipper, Katie E; Chastain, Daniel B; Barber, Katie E.

Afiliação

Wagner JL; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
Jones BM; Department of Pharmacy, St Joseph's/Candler Health System, Inc, Savannah, Georgia, USA.
Stover KR; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
Cleary JD; Department of Pharmacy, St Dominic Jackson-Memorial Hospital, Jackson, Mississippi, USA.
Bland CM; Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Savannah, Georgia, USA.
Schipper KE; Department of Pharmacy, St Dominic Jackson-Memorial Hospital, Jackson, Mississippi, USA.
Chastain DB; Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia, USA.
Barber KE; Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.

Open Forum Infect Dis ; 11(5): ofae217, 2024 May.

Article em En | MEDLINE | ID: mdl-38737432

ABSTRACT

Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved of almost 20 minutes per patient. Daptomycin has the potential to save both time and money.

Palavras-chave

bacterial infection; cost analyses; daptomycin; gram-positive; vancomycin

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article